“RELIANT evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least 2 prior lines of therapy, including treatment with nab-paclitaxel in almost all cases,” said Andreas Grauer, MD, chief medical officer, Corcept Therapeutics. Read more . . .
Relacorilant (CORT125134), a non-steroidal, selective modulator of the glucocorticoid receptor, administered in combination with nab-paclitaxel elicited responses in patients with metastatic pancreatic cancer, leading to the halting of enrollment in the phase 2 RELIANT trial (NCT04329949), according to a press release from Corcept Therapeutics, Inc.